Loading...

Argenica Therapeutics Limited

AGN.AX•ASX
Healthcare
Biotechnology
A$0.67
A$-0.01(-1.47%)

Argenica Therapeutics Limited (AGN.AX) Company Profile & Overview

Explore Argenica Therapeutics Limited’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

Argenica Therapeutics Limited (AGN.AX) Company Profile & Overview

Argenica Therapeutics Limited engages in the research and development of a neuroprotective therapeutic drug in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate use to protect brain cells and reduce cell death during a stroke and other types of neural injuries. The company was incorporated in 2019 and is based in Nedlands, Australia.

SectorHealthcare
IndustryBiotechnology
CEOLiz Dallimore

Contact Information

https://argenica.com.au
61 8 9329 3396
117 Broadway, Nedlands, WA, 6009

Company Facts

IPO DateJun 11, 2021
CountryAU
Actively Trading

Frequently Asked Questions

;